[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":605},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,180,0,25,[9,42,62,85,114,137,160,184,206,226,253,275,295,321,347,369,406,432,450,472,494,516,538,562,587],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100053481","endovascular-treatment-of-chronic-intracranial-artery-occlusion-100053481",false,"NCT07699003","Endovascular Treatment of Chronic Intracranial Artery Occlusion","Endovascular Treatment of Chronic Intracranial Artery Occlusion: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Occlusion of the unilateral middle cerebral artery, basilar artery, intracranial internal carotid artery, or vertebral artery, as confirmed by computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA)\n3. Modified Rankin Scale (mRS) score of 0-2\n4. Presence of symptoms related to the occluded vessel, as determined by the physician, with the most recent symptom onset occurring more than 4 weeks and within 6 months prior to enrolment\n5. The subject or their legally authorised representative has provided written informed consent for the study\n\nExclusion Criteria:\n\n1. Evidence of hemorrhage on CT or MRI\n2. Large hemispheric infarction involving \\>50% of the middle cerebral artery territory on CT or MRI\n3. Severe pre-stroke disability (modified Rankin Scale score ≥2) or life expectancy \\\u003C12 months\n4. Major comorbidities that may interfere with outcome assessment and follow-up (e.g., severe heart failure, renal failure, etc.)\n5. Uncontrolled seizure at the time of stroke onset\n6. Baseline platelet count \\\u003C50,000\u002FμL\n7. Severe, persistent hypertension that remains uncontrolled despite active management (systolic blood pressure \\>220 mmHg or diastolic blood pressure \\>120 mmHg)\n8. Known inherited or acquired bleeding diathesis, coagulation factor deficiency, or recent oral anticoagulant therapy with an international normalized ratio (INR) \\>3\n9. Suspected septic emboli or suspected bacterial endocarditis\n10. Known allergy to iodine, heparin, or anaesthetics, or other definite contraindications to endovascular procedures\n11. Pregnant women\n12. Other severe, progressive, or terminal diseases (as judged by the investigator), or life expectancy \\\u003C24 months\n13. Prior attempted endovascular recanalization therapy before randomization\n14. Current participation in other studies involving investigational drugs or devices\n15. Evidence of intracranial tumour on CT or MRI (except meningioma)\n16. Excessive tortuosity of cervical vessels on CTA\u002FMRA that may preclude endovascular therapy","ALL","18 Years",{"count":20,"type":21},382,"ESTIMATED","INTERVENTIONAL",[24],"NA","Comparison of the efficacy and safety of endovascular treatment versus medical treatment in patients with chronic intracranial artery occlusion.",[27],"Chronic Intracranial Artery Occlusion",[27,29],"stroke","NOT_YET_RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":21},"2026-08-01",{"date":38,"type":21},"2030-08-01",{"name":40,"class":41},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":61,"locationsCount":4},"100053700","endovascular-treatment-for-posterior-circulation-ischemic-stroke-post-1-day-24-hours-100053700","NCT07699029","Endovascular Treatment for Posterior Circulation Ischemic Stroke Post 1 Day （24 Hours）","Endovascular Treatment for Posterior Circulation Ischemic Stroke Post 1 Day （24 Hours） A Randomized Controlled Clinical Trial On Efficacy","ETP1-PC","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Baseline NIHSS score of 4 or higher, maintained prior to randomization\n3. Stroke onset or more than 24 hours since the last known good state, but within 7 days\n4. CTA\u002FMRA\u002FDSA confirmed occlusion of the responsible vessel in basilar artery or intracranial segments of both vertebral arteries (V4)\n5. Modified Rankin Scale (mRS) score of 0 or 1 pre-stroke\n6. The subject or their legally authorized representative has signed the informed consent form for the study\n\nExclusion Criteria:\n\n1. Hemorrhage on CT or MRI\n2. Based on the judgment of the treating physician, the patient is considered unlikely to benefit from the trial (e.g., advanced dementia, severe pre-stroke disability (mRS ≥ 2), or high risk of early mortality)\n3. Major comorbidities that may interfere with outcome assessment and follow-up (e.g., severe heart failure, renal failure, etc.).\n4. Evidence of vascular recanalization prior to randomization\n5. Uncontrolled seizures at the time of stroke onset, if they interfere with obtaining an accurate baseline NIHSS\n6. Posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) \\\u003C 6 on non-contrast CT or CT angiography source images or MR with diffusion-weighted imaging\n7. Complete cerebellar infarct with significant mass effect and compression of the fourth ventricle,or bilateral thalamic infarction on CT or MRI\n8. Baseline platelet count \\\u003C50,000\u002FuL\n9. Severe, persistent hypertension (systolic blood pressure \\> 220 mmHg or diastolic blood pressure \\> 120 mmHg)\n10. Known hereditary or acquired bleeding disorders, coagulation factor deficiencies, or recent oral anticoagulant therapy with an International Normalized Ratio (INR) \\> 3\n11. Suspected purulent embolism, with a suspicion of bacterial endocarditis\n12. Known allergies to iodine, heparin, anesthetics, or other explicit contraindications to the endovascular treatment procedure\n13. Pregnancy\n14. Other serious, progressive, or end-stage diseases (as determined by the investigator) or a life expectancy of less than 6 months\n15. Attempted use of a neurothrombectomy device to remove the clot prior to randomization\n16. Currently participating in a study involving other investigational drugs or devices\n17. Evidence of intracranial tumor on CT or MRI (excluding meningioma)\n18. CTA\u002FMRA showing excessive tortuosity of the cervical vessels, which may interfere with endovascular treatment\n19. Suspicion of aortic dissection based on medical history and CTA\u002FMRA findings\n20. Any other conditions that the investigator believes may interfere with the endovascular procedure or pose significant risk to the subject during the procedure",{"count":51,"type":21},244,[24],"To evaluate the efficacy and safety of endovascular therapy for posterior circulation ischemic stroke presenting more than 24 hours after symptom onset.",[55],"Posterior Circulation Ischemic Stroke",[29,57],"Posterior Circulation",{"date":33,"type":34},{"date":36,"type":21},{"date":38,"type":21},{"name":40,"class":41},{"id":63,"slug":64,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100053938","efficacy-and-safety-of-ganciclovir-capsules-in-the-treatment-of-refractory-moderate-to-severe-allergic-rhinitis-100053938","NCT06436534","Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis","A Randomized, Double-blind, Placebo-controlled, Single-center Clinical Trial of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis","Inclusion Criteria:\n\n1. Aged between 18 and 65 years.\n2. Diagnosed with moderate-to-severe perennial allergic rhinitis based on Chinese guideline for diagnosis and treatment of allergic rhinitis (2022, revision) with Allergic Rhinitis Control Test (ARCT) score \\\u003C20.\n3. Total Nasal Symptom Score (TNSS) ≥6 or at least two of the four subdomains(sneezing, rhinorrhea, nasal itching, and nasal obstruction) ≥2 at the time of both screening and randomization. And the improvement in TNSS was assessed as \\\u003C 30% at randomization compared to screening.\n4. The participant is allergic to dust mites or other perennial allergens\n5. Voluntarily participate in the clinical trial and sign the informed consent.\n\nExclusion Criteria:\n\n1. Participants with hypersensitivity to ganciclovir capsules and its excipients.\n2. Have symptoms of viral infection, fever and other systemic symptoms in the past 2 weeks.\n3. Pregnant or lactating women and participants who have pregnancy plan during the study period.\n4. Participants with severe neutropenia (absolute neutrophil count less than 0.5\\*10\\^9\u002FL) or severe thrombocytopenia (platelet count less than 2.5\\*10\\^10\u002FL).\n5. Comorbidities such as upper and lower respiratory tract infections, history of acute or chronic sinusitis, dry rhinitis, atrophic rhinitis, severe deviated septum and asthma.\n6. Participants with other severe heart, lung, liver and kidney disease.\n7. Participants who had received any live or attenuated vaccine within 4 weeks prior to baseline or intended to receive live or attenuated vaccine (or BCG treatment) during the study period or within 4 weeks after the last administration of the investigational drug product.\n8. Participants with a history of HIV infection or who test positive for HIV serology.\n9. Participants currently infected or chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV).\n10. Participants with cirrhosis and\u002For chronic hepatitis.\n11. Participants who have been diagnosed with active parasitic infections or are at high risk of developing such infections.。\n12. Participants with a known or suspected history of immunosuppression, including a history of invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pneumosporidiosis, aspergillosis). Or participants with what researchers believe to be unusually frequent, recurring, or prolonged infections.\n13. Participants with a known history of malignancy within 5 years prior to screening.\n14. Participants with severe co-morbidities that, in the opinion of the investigator, would adversely affect their participation in this study.\n15. Participants with combined neurological or psychiatric disorders who are unable or reluctant to cooperate.\n16. Participants with disabilities prescribed by law (blind, deaf, mute, mentally challenged, mentally handicapped, etc.).\n17. Participants suspected or having a history of alcohol and drug abuse.\n18. Other participants who have been involved in other clinical trials within 3 months before the screening.\n19. The researchers consider it inappropriate to participate in this clinical trial.","65 Years",{"count":71,"type":21},50,[24],"The goal of this clinical trial is to learn about the clinical efficacy and safety of ganciclovir (GCV) capsules in the treatment of refractory moderate-to-severe allergic rhinitis. The main questions it aims to answer are:\n\n1. Whether ganciclovir improve nasal symptoms and life quality in patients with refractory moderate-to-severe allergic rhinitis.\n2. Whether ganciclovir is safe for the treatment of allergic rhinitis.\n\nParticipants with refractory moderate-to-severe allergic rhinitis will be included in the trial based on the inclusion and exclusion criteria, and randomized into experimental and control groups.\n\nThe two groups will be treated with blinded ganciclovir capsules or placebo for two weeks, with the background therapy of mometasone furoate aqueous nasal spray. A placebo is a look-alike capsule that contains no active drug. Nasal symptom scores, nasal secretions, blood samples and adverse events will be collected during the visits.\n\nResearchers will compare the experimental and control groups to see whether ganciclovir improve symptoms and is safe for the treatment of refractory moderate-to-severe allergic rhinitis.",[75],"Rhinitis, Allergic","RECRUITING","2026-07-09",{"date":33,"type":34},{"date":80,"type":34},"2024-05-24",{"date":82,"type":21},"2026-12",{"name":40,"class":41},1,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100645274","metabolic-and-functional-study-of--t-cells-in-critically-ill-patients-100645274","NCT07680816","Metabolic and Functional Study of γδ T Cells in Critically Ill Patients","Subset-specific Metabolic Adaptation and Functional Remodeling of Gamma Delta T (γδ T) Cells in Critically Ill ICU Patients: A Single-center, Prospective, Observational Cohort Study.","Inclusion Criteria:\n\n1. Healthy Control Group (NHC):\n\n   * Age ≥ 18 years.\n   * No acute or chronic major diseases.\n   * Provide written informed consent.\n2. Non-septic Critical Illness Group (CI-NS):\n\n   * Age ≥ 18 years.\n   * Admitted to the ICU and meeting the definition of critical illness.\n   * Excluded from sepsis according to the Sepsis-3 criteria (infection + ΔSOFA ≥ 2 points).\n   * Written informed consent provided by the participant or legally authorized representative.\n3. Septic Critical Illness Group (CI-Sep):\n\n   * Age ≥ 18 years.\n   * Admitted to the ICU and meeting the Sepsis-3 criteria (infection + ΔSOFA ≥ 2 points).\n   * Written informed consent provided by the participant or legally authorized representative.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Known immunodeficiency, HIV infection, active hematologic malignancy, or history of hematopoietic stem cell or solid organ transplantation within the past 3 months.\n* Receipt of T-cell-targeted immunosuppressive therapy (e.g., antithymocyte globulin, calcineurin inhibitors, mycophenolate mofetil, methotrexate, or high-dose corticosteroids \\>1 mg\u002Fkg\u002Fday prednisone equivalent) before ICU admission or within 24 hours after ICU admission.\n* Use of immune checkpoint inhibitors (e.g., anti-PD-1\u002FPD-L1\u002FCTLA-4 antibodies) within the past 6 weeks.\n* Expected ICU stay \\\u003C 24 hours or imminent risk of death (moribund state).\n* Pregnancy or breastfeeding.\n* Active major bleeding.\n* Inability to obtain informed consent.",true,"80 Years",{"count":95,"type":21},105,"OBSERVATIONAL","This prospective observational cohort study investigates the subset-specific metabolic adaptation and functional remodeling of cytotoxic γδT cells in critically ill patients with and without sepsis. Emerging evidence indicates that γδT cells, as a bridge between innate and adaptive immunity, play a critical role in early anti-infection defense during sepsis. However, the functional status and underlying regulatory mechanisms of cytotoxic γδT cells in septic patients remain incompletely understood. Our preliminary single-cell transcriptomic analysis revealed that cytotoxic γδT cells from septic patients exhibit significant alterations in cytotoxicity-associated molecules (GZMB, PRF1, GNLY) and mitochondrial oxidative phosphorylation (OXPHOS) pathway genes, particularly COX6C, which correlates with cytotoxic effector molecule expression. This study aims to systematically characterize the proportion, cytotoxicity, and mitochondrial metabolic function of circulating cytotoxic γδT cells across three cohorts: healthy controls, critically ill non-septic patients, and critically ill septic patients. By integrating flow cytometry, mitochondrial function assays, and functional validation experiments, we seek to elucidate the role of COX6C-mediated mitochondrial metabolic abnormalities in cytotoxic γδT cell dysfunction, providing theoretical basis for understanding immune dysregulation in sepsis and identifying novel therapeutic targets.",[99,100,101,102,103,104,105],"Sepsis","Critical Illness","Immunosuppression","MODS","Mitochondrial Diseases","Dysbiosis","γδ T Cells","2026-07-01",{"date":108,"type":34},"2026-07-02",{"date":110,"type":21},"2026-07-15",{"date":112,"type":21},"2027-07-15",{"name":40,"class":41},{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":92,"sex":17,"minAge":18,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":84},"100506542","correlation-of-memory-cd8-t-cells-with-sepsis-severity-and-mortality-a-single-center-unblinded-prospective-non-interventional-observational-study-100506542","NCT05875740","Correlation of Memory CD8+ T Cells With Sepsis Severity and Mortality: a Single-center, Unblinded, Prospective, Non-interventional, Observational Study","Inclusion Criteria:\n\nPatients aged 18-60 years old without restriction of gender, race, religion, creed or nationality; No sedative drugs with elimination half-life were used before inclusion in the study; Patients and\u002For their family members know and agree to participate in the trial.\n\nExclusion Criteria:\n\nHistory of solid organ or bone marrow transplantation; Diseases that may affect immune-related indicators, such as autoimmune diseases such as rheumatoid arthritis and SLE, or hematological malignancies such as leukemia and lymphoma; Have received radiotherapy or chemotherapy within the past 30 days, or have received immunosuppressive drugs (tripterygium, mycophenolate, cyclophosphamide, FK506, etc); Pregnancy or lactation; Chronic nephrosis; Severe chronic liver disease (child-Pugh: Grade C); alcohol or opioid dependence, mental illness, or severe cognitive impairment; Patients and\u002For their family members refuse to participate in the trial.","60 Years",{"count":122,"type":21},30,"Sepsis is defined as a life-threatening organ dysfunction that is caused by a dysregulated host response to infection. Severe sepsis is the most common cause of death among critically ill patients in non-coronary intensive care units (ICU). Sustained excessive inflammation and immune dysfunction have been confirmed to play a key role in organ damage and early death of sepsis patients. Therefore, it is important to reduce excessive inflammatory response mediated by immune cells and pro-inflammatory cytokines in the acute phase of sepsis.\n\nSingle-cell RNA sequencing performed on both septic patients and mice suggest that changes in Tcm (CD3+ CD8+ CD44+ CD127+ CD62L+) and Tem (CD3+ CD8+ CD44+ CD127+ CD62L -) in the acute phase of sepsis may play an important role in sepsis. In addition, animal researches showed that Tcm and Tem decreased decreased continuously at 24, 48 and 72h after cecal ligation and perforation (CLP) in mice, and the adoptive transfer of Tcm , sorting from spleen of mice 24h after CLP , but not Tem improved 7-day survival rate of sepsis mice.\n\nThis observational study is aimed to investigate the quantity and proliferation of Tcm and Tem in the acute phase of sepsis and their correlation with severity level and mortality of septic patients in ICU.",[99,125],"Inflammatory Response",[127,128,129,130],"sepsis","CD8+ T cell","central memory CD8+ T cell","inflammatory response",{"date":108,"type":34},{"date":133,"type":34},"2023-09-06",{"date":135,"type":21},"2026-09-30",{"name":40,"class":41},{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":157,"leadSponsor":159,"locationsCount":4},"100644582","fmt-for-90-day-outcome-of-clinical-use-in-icu-sepsis-100644582","NCT07670299","FMT for 90-Day Outcome of Clinical Use in ICU Sepsis","Fecal Microbiota Transplantation for 90-Day Outcome of Clinical Use in ICU Sepsis: a Single-Center, Open-Label, Randomized Controlled Trial","FOCUS","Inclusion Criteria:\n\n* Age ≥ 18 years, any ethnicity, any gender.\n* Diagnosis of sepsis according to the Sepsis-3 criteria (infection with an acute change in SOFA score ≥ 2 points).\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Patients whom the attending clinician considers to have a high risk of death within 5 days, or patients with treatment limitations in place.\n* Active major gastrointestinal bleeding, perforation, or other severe impairment of the intestinal barrier.\n* Patients unable to tolerate enteral nutrition meeting ≥50% of caloric requirements due to severe diarrhea, significant fibrotic intestinal stricture, severe gastrointestinal bleeding, or high-output intestinal fistula.\n* Planned or recent abdominal surgery (within 14 days).\n* Current diagnosis of fulminant colitis or toxic megacolon.\n* Recent receipt of high-risk immunosuppressive or cytotoxic therapy, such as rituximab, doxorubicin, or moderate-to-high-dose corticosteroids (≥20 mg\u002Fday of prednisone or equivalent) for more than 4 consecutive weeks.\n* Pregnant or breastfeeding women.\n* Participation in another clinical trial as a subject at the time of enrollment or within 3 months prior to enrollment.\n* Subjects for whom the validity of informed consent is questionable, including those with psychiatric disorders, intellectual disability, poor motivation, or other conditions that may limit their ability to provide informed consent.","70 Years",{"count":147,"type":21},60,[24],"Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, representing one of the leading causes of death in intensive care units (ICUs) worldwide. Gut microbiota disruption is increasingly recognized as a key driver of persistent inflammation and multiple organ dysfunction in septic patients. Fecal microbiota transplantation (FMT) has emerged as a promising approach to restore gut microbial homeostasis. This study hypothesizes that FMT acts not through long-term engraftment of donor microbes, but via a \"functional pulse\" - a potent, transient biological intervention that delivers high-dose microbial metabolites (e.g., short-chain fatty acids), competitively inhibits pathogens, and rapidly modulates intestinal immune cell functions.\n\nThis is a single-center, open-label, randomized controlled trial conducted in the ICU of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. A total of 60 adult patients diagnosed with sepsis according to Sepsis-3 criteria within 24 hours of ICU admission will be randomized in a 1:1 ratio to receive either ICU standard care alone (control group) or ICU standard care plus FMT administered via a nasojejunal tube for three consecutive days (intervention group). The primary endpoint is all-cause mortality at 90 days. Secondary endpoints include ICU mortality, in-hospital mortality, 28-day mortality, changes in gut microbiota composition and metabolites, serum citrulline levels as a marker of intestinal barrier function, Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, vasopressor requirements, C-reactive protein and procalcitonin levels, fluid balance, incidence of ICU delirium and feeding intolerance, and 90-day hospital readmission rate. Safety outcomes include gastrointestinal symptoms and transient fever.",[99,100,151,104,152],"Gastrointestinal Dysfunction","Fecal Microbiota Transplantation","2026-06-25",{"date":155,"type":34},"2026-06-26",{"date":110,"type":21},{"date":158,"type":21},"2028-10-15",{"name":40,"class":41},{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":92,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":167,"targetDuration":169,"studyType":96,"phases":4,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":181,"leadSponsor":183,"locationsCount":4},"100644180","myeloid-bias-in-the-bone-marrow-of-septic-patients-and-its-correlation-with-disease-severity-and-prognosis-a-single-center-prospective-cohort-study-100644180","NCT07667153","Myeloid Bias in the Bone Marrow of Septic Patients and Its Correlation With Disease Severity and Prognosis: A Single-Center, Prospective Cohort Study","Myeloid Bias in the Bone Marrow of Septic Patients","1\\. Inclusion Criteria\n\n(1) Sepsis-Associated Critical Illness Cohort\n\n* Age 18-80 years, both genders;\n* Meets the Sepsis-3.0 criteria: confirmed or suspected infection with an acute increase in SOFA score of ≥2 points;\n* Admitted to the intensive care unit (ICU) for 48-72 hours at the time of enrolment;\n* Expected ICU length of stay ≥7 days;\n* Written informed consent provided by the patient or their legally authorized representative.\n\n  (2) Non-Septic Critical Illness Cohort\n* Age 18-80 years, both genders;\n* Admitted to the ICU for 48-72 hours with a diagnosis of non-infectious critical illness, including but not limited to: (a) severe acute pancreatitis; (b) major trauma (Injury Severity Score ≥16); (c) post-major surgery (e.g., cardiovascular surgery, hepatectomy); (d) acute cerebrovascular disease (ischaemic stroke, intracerebral haemorrhage); (e) other critical conditions requiring ICU support;\n* Expected ICU length of stay ≥7 days;\n* Written informed consent provided by the patient or their legally authorized representative.\n\n  (3) Healthy Volunteer Control Cohort\n* Age 18-80 years, both genders.\n* No acute or chronic medical history; recent health check-up results are normal.\n* Normal complete blood count: white blood cell count, haemoglobin, and platelet count within the normal reference ranges;\n* Willing and able to provide written informed consent.\n\n  2\\. Exclusion Criteria\n\n  (1) Sepsis-Associated Critical Illness Cohort\n* Haematological disorders: previous or current primary haematological diseases affecting bone marrow haematopoiesis, including leukaemia, myelodysplastic syndromes, aplastic anaemia, multiple myeloma, lymphoma, etc;\n* Active malignancy or receipt of chemotherapy\u002Fradiotherapy within the past 3 years;\n* Immunosuppressed state: (a) use of immunosuppressive agents within the past 3 months (including glucocorticoids ≥0.5 mg\u002Fkg\u002Fday for ≥2 weeks); (b) history of solid organ or haematopoietic stem cell transplantation; (c) HIV infection or AIDS; (d) congenital immunodeficiency;\n* Blood transfusion or bone marrow transplantation within the past 3 months;\n* Severe chronic organ dysfunction: (a) Child-Pugh Class C liver disease; (b) end-stage renal disease (eGFR \\\u003C30 mL\u002Fmin) without regular dialysis;\n* Abnormalities at the puncture site: infection, rash, trauma, or anatomical deformity at the posterior superior iliac spine;\n* Pregnancy or breastfeeding;\n* Moribund state with expected survival \\\u003C24 hours;\n* Participation in another interventional clinical trial within 3 months before or at enrolment;\n* Refusal to sign informed consent by the patient or legal representative.\n\n  (2) Non-Septic Critical Illness Cohort\n* Evidence of infection: confirmed or suspected active infection (including pneumonia, intra-abdominal infection, urinary tract infection, bloodstream infection, etc.) within 48 hours of ICU admission;\n* All other exclusion criteria listed for the Sepsis-Associated Critical Illness Cohort (items 1-10) apply.\n\n  (3) Healthy Volunteer Control Cohort\n* History of infection within the past 1 month;\n* Abnormalities at the puncture site: infection, rash, trauma, or anatomical deformity at the posterior superior iliac spine;\n* Pregnancy or breastfeeding.",{"count":168,"type":21},45,"90 Days","Sepsis remains a leading cause of critical illness worldwide, yet the underlying mechanisms driving its profound and persistent immune dysfunction are incompletely understood. The bone marrow, as the birthplace of all immune cells, plays a central role in orchestrating systemic immune responses. Emerging evidence from animal models suggests that sepsis triggers emergency myeloid-biased hematopoiesis in the bone marrow, characterized by expansion of myeloid progenitors and myeloid-derived suppressor cells (MDSCs) at the expense of lymphoid and erythroid lineages. This bone marrow remodeling precedes peripheral immune alterations and may represent the initiating event of sepsis-induced immunosuppression. However, direct clinical evidence in humans is scarce. This prospective, single-center cohort study aims to systematically characterize bone marrow hematopoietic remodeling in patients with septic shock, compared to critically ill non-septic patients and healthy volunteers, and to determine whether the degree of myeloid lineage bias correlates with disease severity, immunosuppression, and adverse clinical outcomes.\n\nThis study will enroll three cohorts. Bone marrow aspirates and peripheral blood samples will be collected at 48-72 hours post-enrollment for flow cytometric immunophenotyping of hematopoietic stem\u002Fprogenitor cells, MDSC subsets, and PD-L1 expression, as well as cytokine profiling and exploratory single-cell transcriptomics. Rectal swabs will be collected synchronously for 16S rRNA sequencing and untargeted metabolomics to investigate the association between gut microbiota, microbial metabolites, and bone marrow myeloid skewing, testing the gut-bone marrow-immune axis hypothesis. Clinical severity (SOFA\u002FAPACHE II), secondary infections, and 90-day mortality will be assessed to evaluate prognostic value. By integrating bone marrow hematopoiesis, gut microbiome, and clinical outcomes, this study seeks to provide novel mechanistic insights into sepsis-induced immunoparalysis and identify potential biomarkers or therapeutic targets for immune restoration.",[99,172],"Septic Shock",[99,174,175,176],"Bone marrow","Myeloid bias","Prognosis","2026-06-18",{"date":179,"type":34},"2026-06-24",{"date":110,"type":21},{"date":182,"type":21},"2027-12-30",{"name":40,"class":41},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":190,"minAge":18,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":84},"100625594","phase-2-a-single-arm-multicenter-clinical-study-of-becotatug-vedotin-combined-with-zimberelimab-in-the-treatment-of-recurrent-and-metastatic-cervical-cancer-vulvar-cancer-and-vaginal-cancer-100625594","NCT07424664","A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer","Inclusion Criteria:\n\nA subject must meet all of the following criteria to be eligible for enrollment:\n\n1. The subject has a full understanding of the study, voluntarily agrees to participate, and signs the Informed Consent Form (ICF).\n2. Female, aged 18 to 75 years (inclusive).\n3. Life expectancy ≥ 3 months, as assessed by the investigator.\n4. Histologically confirmed squamous cell carcinoma of the cervix, vagina, or vulva.\n5. Have received at least one line of standard therapy, which must have included platinum-based chemotherapy and an immunotherapy agent; prior lines of therapy ≤ 4.\n6. ECOG performance status of 0 or 1.\n7. Presence of at least one measurable target lesion according to the RECIST 1.1 criteria.\n8. Adequate bone marrow function: absolute neutrophil count ≥ 1.5 × 10⁹\u002FL, platelets ≥ 90 × 10⁹\u002FL, hemoglobin ≥ 90 g\u002FL.\n9. Adequate hepatic and renal function: serum creatinine ≤ 1.5 × upper limit of normal (ULN); AST and ALT ≤ 2.5 × ULN (≤ 5 × ULN for subjects with liver metastases); total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for subjects with liver metastases).\n10. Not pregnant or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 28 days prior to enrollment and agree to use an appropriate method of contraception from the time of signing the ICF until 6 months after the last study drug administration.\n11. Agrees to provide blood and histology samples.\n\nExclusion Criteria:\n\nA subject will be ineligible for study enrollment if they meet any of the following criteria:\n\n1. Known hypersensitivity or allergic reaction to any study drug or its components.\n2. Use of a strong CYP3A4 inducer (e.g., anticonvulsants \\[phenytoin, phenobarbital, carbamazepine\\], rifampicin, rifabutin, St. John's Wort) within 2 weeks prior to the first dose of study medication; or use of a strong CYP3A4 inhibitor (e.g., grapefruit juice, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or a strong UGT1A1 inhibitor (e.g., atazanavir, gemfibrozil, indinavir) within 1 week prior to the first dose.\n3. Known central nervous system (CNS) metastases, meningeal metastases, spinal cord metastases or spinal cord compression.\n4. Currently having uncontrolled systemic diseases (e.g., progressive infection, uncontrolled hypertension, diabetes mellitus, etc.), or psychiatric disorders\u002Fsocial conditions that would limit the subject's ability to comply with study requirements or provide written informed consent.\n5. Radiologically confirmed intestinal obstruction; or a medical history of the following diseases: inflammatory bowel disease, extensive bowel resection (partial colectomy or extensive small bowel resection complicated by chronic diarrhea), Crohn's disease, ulcerative colitis.\n6. Active hepatitis B or hepatitis C infection (hepatitis B surface antigen positive with hepatitis B virus DNA \\> 1 × 10³ copies\u002FmL; hepatitis C virus RNA \\> 1 × 10³ copies\u002FmL).\n7. Human immunodeficiency virus (HIV) infection (positive HIV antibody test).\n8. Major surgery or severe trauma within 30 days prior to the first dose, or planned major surgery within 30 days after the first dose (as determined by the investigator).\n9. Pregnant or breastfeeding women; or women of childbearing potential who refuse to adopt effective contraceptive measures.\n10. Any other condition deemed unsuitable for study participation by the investigator.","FEMALE","75 Years",{"count":122,"type":21},[194],"PHASE2","This is a prospective, multicenter, single-arm clinical trial investigating Becotatug Vedotin in combination with Zimberelimab for the treatment of patients with recurrent and metastatic cervical cancer, vulvar cancer, and vaginal cancer. A total of 30 patients are expected to be enrolled. The study consists of a screening period (within 28 days), a treatment period, and a follow-up period (safety follow-up and survival follow-up). Trial treatment will continue until the patient has received Becotatug Vedotin for 1 year, or until disease progression, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.\n\nSubjects will sign the informed consent form and undergo baseline examinations during the screening period. Patients who meet the inclusion and exclusion criteria will enter the treatment period. All subjects will complete the relevant examinations specified in the protocol during treatment to observe safety, tolerability, and efficacy.",[197],"Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms","2026-06-12",{"date":200,"type":34},"2026-06-16",{"date":202,"type":34},"2026-06-11",{"date":204,"type":21},"2028-03-15",{"name":40,"class":41},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":223,"leadSponsor":225,"locationsCount":84},"100642882","fmt-for-feeding-intolerance-due-to-gastrointestinal-dysfunction-in-critically-ill-patients-100642882","NCT07640633","FMT for Feeding Intolerance Due to Gastrointestinal Dysfunction in Critically Ill Patients","Fecal Microbiota Transplantation for Feeding Intolerance Due to Gastrointestinal Dysfunction in Critically Ill Patients: A Single-Center, Single-Blind, Randomized Controlled Trial","FMT-FIT","Inclusion Criteria:\n\n1. Aged 18 to 70 years inclusive, regardless of ethnicity or gender;\n2. Female participants are either non-fertile (i.e., physiologically incapable of pregnancy, including women with ≥2 years of menopause) or have no pregnancy plans;\n3. Have been admitted to the ICU for ≥24 hours;\n4. Expected ICU stay ≥7 days after study enrollment;\n5. Screened positive for ≥1 manifestation of gastrointestinal dysfunction (intra-abdominal hypertension \\[IAH\\], massive gastric retention, diarrhea, lower gastrointestinal paralysis, bowel dilatation); enteral nutrition is then implemented under the guidance of the enteral feeding intolerance (FI) score, and participants with persistent FI after a 3-day trial are formally enrolled;\n6. Participants can actively cooperate or passively complete relevant examinations and follow-up procedures;\n7. Have signed a written informed consent form.\n\nExclusion Criteria:\n\n1. Severe systemic infection in the early resuscitation phase, with hemodynamic instability, insufficient tissue perfusion, or severe fluid-electrolyte and acid-base imbalances;\n2. Patients assessed by clinicians as having a high risk of death within 5 days, or those with restricted treatment decisions;\n3. Active gastrointestinal bleeding, perforation, or other conditions with severe intestinal barrier impairment;\n4. Patients unable to tolerate enteral nutrition meeting 50% of caloric requirements due to severe diarrhea, significant fibrotic intestinal stenosis, massive gastrointestinal bleeding, or high-output enterocutaneous fistula;\n5. Planned or recent abdominal surgery (within 14 days prior to enrollment);\n6. Current diagnosis of fulminant colitis or toxic megacolon;\n7. Neutropenia (neutrophil count \\\u003C 1500 cells\u002FµL);\n8. Patients with congenital or acquired immunodeficiency disorders;\n9. Recent receipt of high-risk immunosuppressive or cytotoxic agents, e.g., rituximab, doxorubicin, or medium-to-high-dose corticosteroids (≥ 20 mg\u002Fday prednisone equivalent) for a duration of \\> 4 weeks;\n10. Pregnant or lactating women;\n11. Participation in another clinical trial as a subject at the time of enrollment or within 3 months prior to enrollment;\n12. Doubtful validity of informed consent: subjects with mental illness, intellectual disability, poor motivation, or other factors that restrict the validity of informed consent for participation in this study.",{"count":147,"type":21},[24],"Critically ill patients admitted to the intensive care unit (ICU) frequently present with gastrointestinal dysfunction and are at elevated risk of malnutrition. Gastrointestinal dysfunction is correlated with adverse clinical outcomes, including prolonged mechanical ventilation duration, extended ICU length of stay, and increased 90-day mortality.\n\nIn critically ill ICU patients, severe gut microbiota dysbiosis and intestinal barrier impairment may occur due to the burden of primary critical illnesses, as well as the administration of proton pump inhibitors and antibiotics. This cascade contributes to a high prevalence of gastrointestinal dysfunction, alongside profound gut-derived systemic inflammatory responses and organ damage. Given the pivotal role of gut microbiota in maintaining intestinal homeostasis, fecal microbiota transplantation (FMT) holds promise as a novel therapeutic strategy for enteral feeding intolerance secondary to gastrointestinal dysfunction in critically ill ICU patients.\n\nThis study intends to deliver FMT via a nasojejunal tube to critically ill patients with gastrointestinal dysfunction admitted to the ICU. Its objectives are to evaluate the intervention's effects on gastrointestinal function recovery and the alleviation of enteral feeding intolerance, while also assessing its impacts on intestinal barrier function, gut microbiota composition and metabolic profiles, serum metabolite signatures, immune-inflammatory responses (including lymphocyte subsets, cytokines, C-reactive protein, and procalcitonin), ICU delirium, ICU sleep quality, and clinical outcomes (encompassing ICU mortality, in-hospital mortality, 28-day all-cause mortality, 90-day all-cause mortality, 90-day readmission rate, and 90-day incidence of secondary infections).",[218,151,219],"Feeding Intolerance","Critically Ill Intensive Care Unit Patients","2026-06-05",{"date":202,"type":34},{"date":106,"type":21},{"date":224,"type":21},"2027-06-30",{"name":40,"class":41},{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":191,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":84},"100616768","phase-1-iaso208-injection-in-the-treatment-of-relapsedrefractory-b-cell-malignancies-100616768","NCT07309900","IASO208 Injection in the Treatment of Relapsed\u002FRefractory B-cell Malignancies","A Single-arm, Open-label Exploratory Clinical Study of IASO208 Injection in the Treatment of Relapsed\u002FRefractory B-cell Malignancies","Inclusion Criteria\n\nSubjects must meet all of the following criteria to be enrolled in this study:\n\n1. Aged ≥18 years and ≤75 years.\n2. Voluntary participation in this study and signing the informed consent form.\n3. Prior histopathological biopsy confirming a diagnosis of one of the following pathological types:\n\n   * Diffuse Large B-Cell Lymphoma (DLBCL), including High-Grade B-Cell Lymphoma (HGBL);\n   * Grade 3b Follicular Lymphoma (FL3b);\n   * DLBCL transformed from indolent lymphoma (FL or MZL);\n   * Primary Mediastinal Large B-Cell Lymphoma (PMBCL) and Mantle cell lymphoma.\n4. For B-cell lymphoma patients with relapsed\u002Frefractory diseases who have failed standard treatment assessed by investigator (including relapse, non-remission, and progression);\n\n   * Relapsed disease is defined as disease relapse or progression occurring ≥12 months after the end of prior therapy.\n   * Refractory disease is defined as disease progression during treatment, best response of stable disease (SD), relapse within 12 months after autologous hematopoietic stem cell transplantation, or disease progression occurring within 12 months after the end of prior therapy.\n5. CD20 positivity confirmed by detection on tumor biopsy specimens obtained after the last relapse or during the screening period.\n6. Presence of at least one measurable lesion according to the Lugano 2014 criteria (nodal lesion with Long Axis Diameter \\[LDi\\] \\>1.5 cm, extranodal lesion with LDi \\>1.0 cm).\n7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.\n8. Life expectancy ≥12 weeks.\n9. Adequate organ function, as demonstrated by the following laboratory results\n\n   1. Hematology: Absolute Neutrophil Count (ANC) ≥1.0 × 10⁹\u002FL; Absolute Lymphocyte Count (ALC) ≥0.3 × 10⁹\u002FL; Platelet count (PLT) ≥50 × 10⁹\u002FL; Hemoglobin (Hb) ≥70 g\u002FL (must not have received any Granulocyte Colony-Stimulating Factor \\[G-CSF\\] or Granulocyte-Macrophage Colony-Stimulating Factor \\[GM-CSF\\] treatment, or transfusion of red blood cells or platelets within 7 days prior to the laboratory assessment).\n   2. Liver function: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 3 × Upper Limit of Normal (ULN); Total Bilirubin ≤ 2 × ULN (for subjects with documented liver involvement by tumor: ALT\u002FAST ≤5 × ULN; Total Bilirubin ≤3 × ULN).\n   3. Cardiac function: Left Ventricular Ejection Fraction (LVEF) ≥50%, as measured by echocardiography or Multigated Acquisition (MUGA) scan.\n   4. Oxygen saturation \\>92% (by pulse oximetry) at rest.\n   5. Renal function: Creatinine Clearance (CrCl) ≥40 mL\u002Fmin, calculated using the Cockcroft-Gault formula.\n   6. Coagulation profile: Fibrinogen ≥1.0 g\u002FL; Activated Partial Thromboplastin Time (aPTT) ≤1.5 × ULN; Prothrombin Time (PT) ≤1.5 × ULN.\n10. Subjects of childbearing potential must agree to use highly effective contraceptive methods from the time of signing the informed consent form until at least 1 year after the last dose of IASO208 injection.\n\nExclusion Criteria\n\nSubjects who meet any of the following criteria will be excluded from this study:\n\n1. Subjects with central nervous system involvement.\n2. Subjects who have had other malignancies within 5 years prior to screening, except for appropriately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer, ductal carcinoma in situ of the breast, or papillary thyroid carcinoma.\n3. Subjects who meet any of the following conditions in infectious disease screening:\n\n   1. Subjects positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with abnormal peripheral blood HBV DNA test (abnormal HBV DNA is defined as: quantitative detection higher than the lower limit of detection \\[LLD\\], above the normal range, or positive qualitative detection).\n   2. Subjects positive for hepatitis C virus (HCV) antibody with positive peripheral blood HCV RNA.\n   3. Subjects positive for human immunodeficiency virus (HIV) antibody.\n   4. Subjects with syphilis.\n   5. Subjects with active cytomegalovirus (CMV) infection.\n4. Uncontrolled active bacterial, fungal, or viral infection prior to enrollment, as evidenced by:\n\n   1. Persistent infection-related symptoms\u002Fsigns requiring intravenous anti-infective therapy; or\n   2. No improvement in clinical symptoms or examinations after appropriate anti-infective therapy.\n5. Severe cardiac diseases, including but not limited to: unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association \\[NYHA\\] Class ≥ III), or severe arrhythmia.\n6. History of central nervous system diseases or disorders within 6 months prior to screening, such as epilepsy, paralysis, aphasia, cerebral infarction, cerebral hemorrhage, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome (e.g., cerebral aneurysm, epilepsy, stroke \\[except for lacunar infarction\\], dementia, psychosis), or subjects with impaired consciousness.\n7. Previous solid organ transplantation.\n8. Previous allogeneic hematopoietic stem cell transplantation (allo-HSCT), allogeneic CAR-T therapy, or other allogeneic donor adoptive cell therapies.\n9. Subjects who do not meet the required washout periods for the following prior therapies\u002Ftreatments before enrollment:\n\n   1. Cytotoxic chemotherapy, monoclonal antibodies, bispecific antibodies, or antibody-drug conjugates (ADCs) within 4 weeks prior to enrollment.\n   2. Ongoing requirement for systemic corticosteroids or other immunosuppressive therapy within 4 weeks prior to enrollment.\n   3. Radiotherapy or major surgery of Grade 4 severity within 4 weeks prior to enrollment; or planned general anesthesia surgery within 12 weeks after receiving the study treatment.\n   4. Vaccination or treatment with any investigational products within 4 weeks prior to enrollment.\n   5. Autologous hematopoietic stem cell transplantation or autologous CAR-T therapy within 12 weeks prior to enrollment.\n10. Presence of other unstable systemic diseases, as determined by the investigator, including but not limited to severe hepatic, renal, or metabolic diseases requiring treatment.\n11. Adverse events from previous anti-tumor therapies have not resolved to baseline or Grade ≤ 2 (excluding alopecia, fatigue, and peripheral neuropathy).\n12. Known history of hypersensitivity to any excipient component of the IASO208 injection.\n13. Pregnant or lactating women.\n14. Any other condition deemed by the investigator as inappropriate for participation in the study.",{"count":234,"type":21},12,[236],"PHASE1","This is an investigator-initiated, single-arm, open-label clinical study. It employs a dose-escalation design to evaluate the safety, pharmacokinetics, and preliminary efficacy of IASO208 injection in relapsed\u002Frefractory B-cell malignancies.",[239],"Relapsed\u002FRefractory B-cell Malignancies",[241,242,243,244],"in vivo CAR-T","CD20","IASO208","Relapsed\u002F Refractory B-cell malignancies","2026-05-27",{"date":247,"type":34},"2026-06-01",{"date":249,"type":34},"2025-11-21",{"date":251,"type":21},"2029-06-15",{"name":40,"class":41},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":17,"minAge":260,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":4},"100638654","phase-2-xiaochaihu-granules-for-depression-after-allogeneic-hematopoietic-stem-cell-transplantation-100638654","NCT07608029","Xiaochaihu Granules for Depression After Allogeneic Hematopoietic Stem Cell Transplantation","A Single-Center, Prospective, Randomized, Parallel-Assignment, Phase II Study Evaluating Two Dose Levels of Xiaochaihu Granules for Depression After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\n  1. Able to understand the study procedures and voluntarily provide written informed consent (or consent from a legal guardian where applicable);\n  2. Age ≥14 years, male or female;\n  3. Patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT);\n  4. Newly diagnosed depression after allo-HSCT, assessed by standardized scales (e.g., HADS and\u002For HAMD);\n  5. Evidence of successful neutrophil engraftment prior to enrollment;\n  6. Willing and able to comply with study procedures and follow-up assessments.\n\nExclusion Criteria:\n\n1. Refusal to participate in the study;\n2. Presence of severe psychiatric disorders or severe somatic symptom disorders;\n3. Known allergy to Xiaochaihu Granules or any of its components;\n4. Current use of other antidepressant medications;\n5. Severe organ dysfunction or unstable clinical condition, including but not limited to:\n\n   Uncontrolled bloodstream infection; Expected survival \\\u003C3 months;\n6. History of splenectomy;\n7. Renal insufficiency with serum creatinine ≥2.0 mg\u002FdL;\n8. Cholestatic liver disease or unresolved hepatic veno-occlusive disease (VOD);\n9. Significant cardiovascular conditions, including:\n\n   Unstable angina; Acute myocardial infarction within 6 months prior to enrollment; NYHA class III-IV heart failure; Circulatory failure requiring vasoactive or inotropic support; Clinically significant arrhythmia requiring treatment;\n10. Severe respiratory disease requiring mechanical ventilation or ≥50% oxygen support;\n11. Patients whose primary disease is in complete remission after transplantation (per protocol definition);\n12. Participation in another interventional clinical trial within 21 days prior to enrollment (or within 5 half-lives of the investigational product, whichever is longer);\n13. Any other condition deemed by the investigator to make the patient unsuitable for participation.","14 Years",{"count":262,"type":21},46,[194],"This is a single-center, prospective, randomized, dose-escalation Phase II clinical study. A total of 46 patients with newly diagnosed depression following allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be enrolled.\n\nParticipants will be randomly assigned to receive different doses of Xiaochaihu Granules in addition to standard post-transplant care for 100 days. The primary objective is to evaluate the efficacy of Xiaochaihu Granules in improving depressive symptoms. Secondary objectives include assessment of safety and clinical outcomes such as event-free survival (EFS), graft-versus-host disease (GVHD), infections, and other transplantation-related complications.",[266,267],"Depressive Disorder, Secondary","Hematopoietic Stem Cell Transplantation","2026-05-25",{"date":245,"type":34},{"date":271,"type":21},"2026-05-16",{"date":273,"type":21},"2029-09-30",{"name":40,"class":41},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":69,"enrollmentInfo":281,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":84},"100580924","clinical-application-of-pet-imaging-targeting-msln-in-malignant-tumors-100580924","NCT06843629","Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors","Inclusion Criteria:\n\n* Each subject must meet all enrollment criteria to be eligible to participate in the study:\n\n  1. The subject or his\u002Fher legal representative is able to sign and date the informed consent form;\n  2. A commitment to comply with the research procedures and to cooperate in the implementation of the full research process;\n  3. Adult patients or healthy volunteers (aged 18 or above) of either sex;\n  4. Patients with clinically suspected or confirmed malignant tumors such as pancreatic cancer, ovarian cancer, or lung adenocarcinoma (supporting evidence includes serum-related tumor markers, imaging data such as ultrasound, CT, MRI, etc., and histological pathology examination, etc.) and in good general condition;\n  5. Consistent with the results of specific laboratory tests;\n  6. Females of childbearing potential who have been using contraception for at least one month prior to screening and who are committed to using contraception for the entire study period and until a specified time after the end of the study；\n  7. Other set entry criteria.\n\nExclusion Criteria:\n\n* All subjects who meet any of the exclusion criteria baseline will be excluded from the study:\n\n  1. Those who are unable to complete a PET\u002FMR or PET\u002FCT examination (including inability to lie down, claustrophobia, radiophobia, etc.);\n  2. Having other comorbidities;\n  3. Patients with known hypersensitivity to MSLN antibody fragment developers or synthetic excipients; fasting blood glucose level greater than 11.0 mmol\u002FL prior to 18F-FDG injection；\n  4. Have a history of comorbid drug use;\n  5. Patients considered by the investigator to have poor compliance;\n  6. Patients during pregnancy or lactation;\n  7. Persons with other factors that make participation in this test inappropriate.",{"count":282,"type":21},100,"The project aims to perform integrated PET\u002FMR or PET\u002FCT visualization of patients with clinically suspected or confirmed pancreatic cancer, ovarian cancer, lung adenocarcinoma and other malignant tumors with high MSLN expression and healthy volunteers, using targeted MSLN-specific imaging agents (taking \\[68Ga\\]Ga-NOTA-MSLN antibody fragment as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \\[18F\\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.",[285,286,287],"Ovarian Cancer","Lung Adenocarcinoma","Pancreatic Cancer",{"date":289,"type":34},"2026-05-28",{"date":291,"type":34},"2024-10-01",{"date":293,"type":21},"2028-06-30",{"name":40,"class":41},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":17,"minAge":260,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":318,"leadSponsor":320,"locationsCount":84},"100640219","blood-exosomal-multi-omics-and-lung-radiomics-for-predicting-efficacy-and-prognosis-of-severe-eosinophilic-acos-with-biologics-100640219","NCT07602881","Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS With Biologics","Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS (Asthma-COPD Overlap Syndrome) Treated With Different Biologics: A Real-World Observational Study","ACOS","Inclusion Criteria:\n\n* Age ≥ 14 years\n* Clinician decision to start biologic (benralizumab, mepolizumab, or dupilumab) for severe eosinophilic ACOS\n* Blood eosinophils ≥150\u002FμL within 3 months prior to informed consent, or ≥300\u002FμL within 1 year prior\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Currently participating in any other interventional clinical trial\n* Known allergy or hypersensitivity to any component of the study drugs\n* Any type of malignancy\n* Prior or current biologic treatment for ACOS",{"count":304,"type":21},500,"Firstly, to screen blood exosomal multi-omics (transcriptomics, proteomics, metabolomics) and lung radiomics (HRCT, Xe129MRI) biomarkers that can predict efficacy and prognosis in severe eosinophilic ACOS (asthma-COPD overlap) patients treated with different biologics (benralizumab, mepolizumab, dupilumab). Then, to prospectively follow patients for 48 weeks after biologic initiation and collect clinical data, blood samples, and imaging features. Finally, to build a multi-dimensional predictive model for efficacy and prognosis of severe eosinophilic ACOS.",[307],"Severe Eosinophilic ACOS (Asthma-COPD Overlap)",[309,310,311,312,313],"Biomarker","Exosomal Multi-omics","Radiomics","Biologics","Severe Eosinophilic ACOS","2026-05-21",{"date":316,"type":34},"2026-05-22",{"date":247,"type":21},{"date":319,"type":21},"2028-07-01",{"name":40,"class":41},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":92,"sex":190,"minAge":4,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":343,"leadSponsor":345,"locationsCount":346},"100640593","autofuse-or-first-trimester-ultrasound-scan-100640593","NCT07601191","AutoFUSE or First-Trimester Ultrasound Scan","Validation of an AI-based Intelligent Image Quality Control System for First-Trimester Ultrasound Scan: a Stepwise, Multicenter, Randomized Clinical Trial in China","Inclusion Criteria:\n\n① Pregnant women undergoing fetal ultrasound examination.\n\n② A singleton pregnancy with a live fetus between 11 and 13+6 weeks with complete outcomes.\n\nExclusion Criteria:\n\n* Incomplete pregnancy outcome information.\n\n  * Unexplained miscarriages. ③ Fetal death.\n\n    * Pregnancies with significant maternal complications.\n\n      * Multiple pregnancies.",{"count":329,"type":21},1000,[24],"The goal of this clinical trial is to validate the clinical application capabilities of AutoFUSE. The main questions it aims to answer are:\n\nDoes AutoFUSE reduce the time required to obtain standard planes in first-trimester ultrasound scan? Does AutoFUSE improve the accuracy of standard plane acquisition in first-trimester ultrasound scan? What safety outcomes occur in participants undergoing AutoFUSE-assisted ultrasound examination? Researchers will compare AutoFUSE-assisted ultrasound scan with standard clinical protocol (SCP) ultrasound scan to evaluate the efficacy and safety of AutoFUSE in clinical practice.\n\nParticipants will:\n\nUndergo either AutoFUSE-assisted ultrasound scan or standard clinical ultrasound scan according to the study design.\n\nComplete scheduled visits for examinations, data collection and follow-up. Provide information related to scan time, image quality and safety during the study.",[333],"Fetus Disorder",[335,336,337,338,339],"First-trimester ultrasound","Artificial intelligence","Standard plane","Image quality control","Randomized clinical trial","2026-05-20",{"date":316,"type":34},{"date":247,"type":21},{"date":344,"type":21},"2026-12-31",{"name":40,"class":41},3,{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":190,"minAge":18,"maxAge":145,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":84},"100623738","phase-3-a-clinical-study-on-the-treatment-of-lacc-with-cadonilimab-combined-with-chemotherapy-followed-by-ccrt-100623738","NCT07400536","A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT","A Phase III, Multicenter, Open-label, Randomized Controlled Clinical Study on the Treatment of Locally Advanced Cervical Cancer With Cadonilimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy","Inclusion Criteria:\n\nTo be enrolled, subjects had to meet all of the following criteria:\n\n1. Female, aged 18-70 years (inclusive of cutoff values);\n2. Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix;\n3. Patients with stage IIB-IVA cervical cancer (FIGO stage 2018) who had not received any previous antineoplastic therapy;\n4. At least one measurable lesion according to RECIST v1.1;\n5. Eastern Cooperative Oncology Group (ECOG) performance-status score 0-1;\n6. Have adequate organ function.\n\nExclusion Criteria:\n\nSubjects were excluded from the study if they met any of the following criteria:\n\n1. Distant metastatic disease (including inguinal lymph node metastasis and lymph node metastasis above the level of the superior edge of the L1 pyramid in the proximal cephalic region, according to FIGO 2018 stage IVB);\n2. He had undergone total hysterectomy (removal of the corpus uteri and cervix);\n3. Inability to undergo brachytherapy or refusal to undergo brachytherapy for reasons such as anatomical abnormalities;\n4. Had received any previous antineoplastic therapy, including but not limited to surgery (except biopsy), radiotherapy, or systemic therapy (chemotherapy, immunotherapy, targeted therapy);\n5. Had any condition that was deemed by other investigators to be ineligible for participation in the trial.",{"count":355,"type":21},378,[357],"PHASE3","This study mainly evaluated the efficacy and safety of Cadonilimab combined with chemotherapy followed by concurrent chemoradiotherapy versus standard concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer.",[360],"Locally Advanced Cervical Carcinoma","2026-05-08",{"date":363,"type":34},"2026-05-13",{"date":365,"type":34},"2026-04-24",{"date":367,"type":21},"2032-07-20",{"name":40,"class":41},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":191,"enrollmentInfo":376,"targetDuration":4,"studyType":22,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":4},"100640348","phase-1-a-study-of-in026-in-participants-with-refractory-gout-100640348","NCT07587684","A Study of IN026 in Participants With Refractory Gout","A Clinical Study on the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of IN026 in the Treatment of Refractory Gout","Inclusion Criteria:\n\n1. Can voluntarily sign the informed consent form (ICF) and comply with ICF and study protocol requirements.\n2. Male or female, 18-75 years old (inclusive) at screening.\n3. Meet 2015 ACR\u002FEULAR gout classification criteria, in the intercritical phase of gout or acute flare resolved ≥2 weeks at screening.\n4. Serum uric acid ≥420 μmol\u002FL (7 mg\u002Fdl) at screening.\n5. Meet the definition of refractory gout (poor uric acid control accompanied by severe gout symptoms)\n\nExclusion Criteria:\n\n1. Gout secondary to radiotherapy\u002Fchemotherapy, lead poisoning, organ transplantation, tumor, etc. at screening\u002Fbaseline.\n2. Rheumatoid arthritis, infectious\u002Fseptic arthritis, or other acute inflammatory arthritis at screening\u002Fbaseline.\n3. Glucose-6-phosphate dehydrogenase (G6PD) deficiency history, or G6PD level below normal lower limit.\n4. Positive HBsAg; HCV antibody positive is excluded except those with sustained HCV-RNA negativity after standard treatment; HIV antibody positive; active syphilis.\n5. Presence of chronic liver diseases including active hepatitis, cirrhosis and alcoholic liver disease.\n6. Participants with a history of any of the following: serious cardiovascular diseases within 6 months prior to screening; or serious diseases of the digestive, respiratory, urinary, musculoskeletal, neuropsychiatric, hematological, or immune systems within 3 months prior to screening.\n7. Prolonged QTcF at screening.\n8. Uncontrolled or untreated hypertension at screening.\n9. Participants who have received medications that may affect endpoint assessment, such as other urate-lowering therapies, mRNA-LNP vaccine, PEGylated drugs and uricase agents.\n10. History of severe allergy, or known allergy to IN026 or its components.\n11. Participation in other clinical trials within 30 days prior to screening.\n12. Participants with poor compliance, or those deemed otherwise unsuitable for this study by the investigator.",{"count":377,"type":21},16,[236],"The goal of this clinical study is to learn if IN026 Injection is safe and works to lower uric acid levels in adults with refractory gout (gout that does not respond well to standard treatments). The main questions it aims to answer are:\n\n* What medical problems do participants have when taking IN026, such as changes in vital signs, blood tests, or heart rhythm?\n* How does the body absorb, process, and respond to IN026, and does it trigger an immune reaction?\n* Does IN026 lower uric acid levels in the blood and reduce tophi?\n\nInvestigator will start with lower doses of IN026 and slowly increase the dose to find the well-tolerated dose.\n\nParticipants will:\n\n* Receive IN026 through an intravenous (IV) drip into a vein at a set dose.\n* Complete a screening period of up to 4 weeks, followed by treatment and check-ups for up to 20 weeks.\n* Have blood and urine samples taken at set times to check safety and how the body responds to IN026.",[381],"Refractory Gout",[383,384,385,386,387,388,381,389,390,391,392,393,394,395,396,397],"Uricase","Gout","Uric acid","IN026","hyperuricemia","Metabolic Diseases","Safety","Pharmacokinetics","Pharmacodynamics","Efficacy","mRNA-LNP medicine","Rheumatic Diseases","Messenger RNA","Urate oxidase","immunogenicity","2026-05-07",{"date":400,"type":34},"2026-05-14",{"date":402,"type":21},"2026-05",{"date":404,"type":21},"2028-05",{"name":40,"class":41},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":69,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":417,"conditions":418,"keywords":423,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":431},"100638272","early-phase-1-a-clinical-study-to-evaluate-lvivo-tavec400-for-the-treatment-of-relapsedrefractory-autoimmune-diseases-100638272","NCT07583030","A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed\u002FRefractory Autoimmune Diseases","A Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the LVIVO-TaVec400 in the Treatment of Relapsed\u002FRefractory Autoimmune Diseases","Inclusion Criteria:\n\n* Subjects voluntarily participate in clinical studies.\n* Age 18-65 years.\n* Adequate organ function at screening.\n* Clinical laboratory values meet criteria at screening visit.\n\n  r\u002Fr SLE:\n* Patients meet the 2019 American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR) OR 2012 Systemic lupus international collaborating clinics (SLICC) classification criteria for SLE at least 6 months before screening.\n* At screening, antinuclear antibody, and\u002For anti-dsDNA antibody, and\u002For anti-Smith antibody should be positive.\n* Fulfill relapsed\u002Frefractory SLE conditions.\n\n  r\u002Fr IgG4-RD：\n* Patients meet the 2019 American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR) classification criteria for IgG4-RD.\n* Fulfill relapsed\u002Frefractory IgG4-RD conditions.\n* Patients have active disease: IgG4-RD Response Index (RI) ≥2.\n\nProgressive MS：\n\n* Diagnosis of MS according to 2017 revised McDonald criteria.\n* Progressive MS according to clinical course criteria revised in 2013.\n* Presence of Cerebrospinal fluid (CSF) oligoclonal bands (OCBs) or elevated IgG Index at screening.\n\n  r\u002Fr MG：\n* Diagnosis of MG.\n* Myasthenia Gravis Foundation of America (MGFA) Class II-IV.\n* Positive AChR-IgG or MuSK-IgG at screening.\n* Fulfill refractory MG conditions.\n\nExclusion Criteria:\n\n* Active infections such as hepatitis and tuberculosis.\n* Coexist other autoimmune or inflammatory diseases.\n* Severe underlying diseases such as tumor, uncontrolled diabetes and severe heart diseases.\n* Female subjects who are pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving LVIVO-TaVec400 treatment.",{"count":414,"type":21},44,[416],"EARLY_PHASE1","This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed\u002Frefractory autoimmune diseases.",[419,420,421,422],"Relapsed\u002FRefractory Systemic Lupus Erythematosus (r\u002Fr SLE)","Relapsed\u002FRefractory IgG4-Related Disease (r\u002Fr IgG4-RD)","Progressive Multiple Sclerosis (PMS)","Relapsed\u002FRefractory Myasthenia Gravis(r\u002Fr MS)",[424],"Relapsed\u002FRefractory autoimmune diseases",{"date":363,"type":34},{"date":427,"type":21},"2026-04-20",{"date":429,"type":21},"2041-09-20",{"name":40,"class":41},5,{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":191,"enrollmentInfo":439,"targetDuration":4,"studyType":22,"phases":440,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":449,"locationsCount":84},"100631284","early-phase-1-a-study-of-ykst02-in-participants-with-primary-iga-nephropathy-100631284","NCT07498673","A Study of YKST02 in Participants With Primary IgA Nephropathy","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of YKST02 in Participants With Primary IgA Nephropathy","Inclusion Criteria:\n\n* Diagnosis of primary IgA nephropathy (IgAN)\n* Proteinuria above a protocol-defined threshold at screening\n* Receiving stable standard-of-care therapy for IgAN for an adequate duration prior to enrollment, unless contraindicated or not tolerated\n* Women of childbearing potential must have a negative pregnancy test prior to study drug administration and agree to use effective contraception; male participants must agree to use effective contraception\n* Able to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Secondary IgA nephropathy (e.g., associated with liver disease, autoimmune disorders, infections, or other systemic conditions)\n* Other clinically significant renal diseases unrelated to IgAN (e.g., diabetic nephropathy, lupus nephritis, vasculitis)\n* Nephrotic syndrome considered unsuitable for study participation\n* Rapidly progressive glomerulonephritis or rapidly declining renal function\n* Estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73 m²\n* Immunodeficiency or low immunoglobulin G (IgG) levels below normal\n* Clinically significant abnormal laboratory findings (e.g., hematologic, hepatic, or coagulation abnormalities)\n* Requirement for systemic corticosteroids for concomitant conditions\n* Use of immunosuppressive, targeted, or biologic therapies within a defined period prior to screening or anticipated use during the study\n* Prior treatment with B-cell-depleting or other targeted biologic therapies within a defined period\n* History of demyelinating disorders (e.g., multiple sclerosis)\n* Clinically significant cardiovascular or cerebrovascular disease within 6 months prior to screening\n* History of organ transplantation or planned transplantation during the study\n* Current dialysis or anticipated need for dialysis during the study\n* Major surgery within 4 weeks prior to screening or planned during the study\n* Active infection requiring systemic therapy, recent serious infection, or chronic\u002Frecurrent infections\n* Known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection\n* Active or untreated latent tuberculosis\n* History of splenectomy\n* Uncontrolled comorbidities (e.g., poorly controlled hypertension or diabetes)\n* Malignancy within the past 5 years, except adequately treated non-invasive cancers\n* Known hypersensitivity to YKST02 or its components\n* Receipt of another investigational product within 4 weeks or 5 half-lives (whichever is longer) prior to screening\n* Receipt of live or attenuated vaccines within 4 weeks prior to screening or planned during the study\n* Any condition that, in the investigator's judgment, would make the participant unsuitable for the study",{"count":234,"type":21},[416],"The goal of this clinical trial is to evaluate the safety and tolerability of YKST02 and to explore its potential to treat adults with primary IgA nephropathy (IgAN). The study will also assess how the drug moves through the body and how it affects the immune system.\n\nThe main questions it aims to answer are:\n\n* Is YKST02 safe and well tolerated?\n* Does YKST02 reduce protein levels in the urine?\n* How does YKST02 behave in the body (pharmacokinetics, PK)?\n* How does YKST02 affect the immune system (pharmacodynamics, PD)? Participants are adults with IgAN who have persistent proteinuria despite standard treatment.\n\nParticipants will:\n\n* Receive YKST02 by intravenous (IV) infusion\n* Be monitored after each dose for safety\n* Attend clinic visits for safety assessments and laboratory tests\n* Provide blood and urine samples during the study and follow-up period",[443],"Primary IgA Nephropathy",{"date":445,"type":34},"2026-05-12",{"date":447,"type":34},"2026-05-06",{"date":224,"type":21},{"name":40,"class":41},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":69,"enrollmentInfo":457,"targetDuration":459,"studyType":96,"phases":4,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100636977","salvage-haploidentical-hsct-with-dli-and-targeted-therapy-for-rr-aml-100636977","NCT07572695","Salvage Haploidentical HSCT With DLI and Targeted Therapy for R\u002FR AML","Salvage Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation Combined With Post-transplant Relapse Prevention Strategies for Relapsed\u002FRefractory Acute Myeloid Leukemia (AML): A Prospective Observational Study","Inclusion Criteria:\n\n* Signed and dated informed consent Willing and able to comply with all study procedures and follow-up Adults aged 18 to 65 years Diagnosis of acute myeloid leukemia (AML) Active disease before transplantation, defined as bone marrow blasts \\>5% or presence of extramedullary disease HCT-CI (Hematopoietic Cell Transplantation-Comorbidity Index) score ≤5\n\nExclusion Criteria:\n\n* Bone marrow blasts ≤5% without extramedullary disease before transplantation Age \\\u003C18 years or \\>65 years HCT-CI score \\>5 Patients with other diagnoses besides AML",{"count":458,"type":21},40,"24 Months","This is a prospective, single-center, observational study to evaluate the efficacy and safety of salvage haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) combined with post-transplant relapse prevention strategies in patients with relapsed\u002Frefractory acute myeloid leukemia (R\u002FR AML).\n\nEligible patients are adults aged 18-65 years with active AML (bone marrow blasts \\>5% or extramedullary disease) and HCT-CI score ≤5. All patients will receive a uniform conditioning regimen consisting of fludarabine, busulfan, and MECCNU, with addition of targeted agents (such as sorafenib, midostaurin, or venetoclax) according to mutation status. Graft-versus-host disease (GVHD) prophylaxis includes reduced-dose ATG (6 mg\u002Fkg), FK506, MMF, and basiliximab. Post-transplant maintenance with targeted therapy or azacitidine and prophylactic donor lymphocyte infusion (DLI) will be administered to reduce relapse risk.\n\nThe primary endpoints are cumulative incidence of relapse (CIR), overall survival (OS), and progression-free survival (PFS). Secondary endpoints include incidence of acute and chronic GVHD, CMV\u002FEBV reactivation, non-relapse mortality (NRM), and GVHD-free, relapse-free survival. Patients will be followed for 24 months after transplantation. This study aims to explore an optimized transplant strategy to improve long-term survival in this high-risk population.",[462,463,464],"Acute Myeloid Leukemia","Relapsed\u002FRefractory Acute Myeloid Leukemia","AML, Relapsed\u002FRefractory","2026-05-03",{"date":398,"type":34},{"date":468,"type":21},"2026-04-30",{"date":470,"type":21},"2028-12",{"name":40,"class":41},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":260,"maxAge":69,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":84},"100636975","phase-2-moxibustion-for-steroid-refractory-acute-graft-versus-host-disease-after-allogeneic-hematopoietic-stem-cell-transplantation-100636975","NCT07572669","Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation","A Prospective, Multicenter, Open-Label, Phase II Study to Evaluate the Safety and Efficacy of Moxibustion in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\nAge 14 to 65 years, male or female. Underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Diagnosis of acute graft-versus-host disease (aGVHD) according to standard criteria, with gastrointestinal involvement (e.g., abdominal pain and diarrhea), and classified as grade II-IV.\n\nSteroid-refractory or steroid-dependent aGVHD, defined as:\n\nDisease progression within 3 days of systemic corticosteroid treatment, or No response within 7 days, or Failure to achieve complete response after 28 days of immunosuppressive therapy, or Recurrence or worsening during steroid tapering. Absolute neutrophil count ≥ 0.5 × 10⁹\u002FL for at least 3 consecutive days. Traditional Chinese medicine (TCM) syndrome differentiation consistent with spleen-kidney yang deficiency.\n\nFemale participants of childbearing potential must have a negative pregnancy test at screening and agree to use effective contraception during the study.\n\nMale participants must agree to use effective contraception during the study. Ability to understand and willingness to sign a written informed consent form. Willingness and ability to comply with study procedures and follow-up.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\nPrior treatment with ≥1 systemic therapy for aGVHD other than corticosteroids. Diagnosis of GVHD overlap syndrome according to NIH criteria. History of splenectomy after transplantation. Evidence of relapse of the underlying disease or receipt of anti-relapse therapy after transplantation.\n\nUnresolved toxicities or complications from prior transplantation (excluding GVHD).\n\nPrior moxibustion therapy after transplantation. Uncontrolled active infection. Known human immunodeficiency virus (HIV) infection. Active hepatitis B or C infection requiring treatment, or risk of HBV reactivation.\n\nReceipt of other investigational therapy within 21 days prior to enrollment (or within 5 half-lives, whichever is longer).\n\nRenal dysfunction: serum creatinine ≥ 2.0 mg\u002FdL or creatinine clearance \\\u003C 40 mL\u002Fmin.\n\nHepatic dysfunction unrelated to GVHD, including cholestatic disease or unresolved hepatic veno-occlusive disease.\n\nSevere cardiovascular disease, including unstable angina, myocardial infarction within 6 months, NYHA class III-IV heart failure, or circulatory failure requiring vasoactive support.\n\nSevere respiratory disease requiring mechanical ventilation or ≥50% oxygen support.\n\nUse of high-dose corticosteroids (≥1 mg\u002Fkg\u002Fday methylprednisolone or equivalent) for non-GVHD indications within 7 days prior to enrollment.\n\nPregnant or breastfeeding women. Severe skin damage or known allergy\u002Fintolerance to study-related procedures. Any other condition that, in the investigator's judgment, would interfere with study participation.",{"count":480,"type":21},42,[194],"This study is a prospective, multicenter, open-label, phase II clinical trial designed to evaluate the safety and efficacy of moxibustion in patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT).\n\nA total of 42 patients with SR-aGVHD, primarily involving the gastrointestinal tract and presenting with abdominal pain and diarrhea, will be enrolled. All participants will receive standard second-line therapy based on best available treatment (BAT), including ruxolitinib, basiliximab, or methotrexate, according to clinical judgment. In addition, patients will receive moxibustion at specific acupoints (Tianshu \\[ST25\\], Shenque \\[CV8\\], and Qihai \\[CV6\\]) for 30 minutes once or twice daily for 28 days.\n\nThe primary endpoint is the overall response rate (ORR) at Day 28. Secondary endpoints include durable ORR at Day 56, incidence and severity of chronic GVHD (cGVHD), non-relapse mortality (NRM), overall survival (OS), and changes in traditional Chinese medicine (TCM) syndrome scores. Safety will be assessed by monitoring adverse events throughout the study period.\n\nThis study aims to explore whether moxibustion, as an adjunctive therapy, can improve clinical outcomes and provide a safe and effective treatment strategy for patients with SR-aGVHD after allo-HSCT.",[484,485,486,487],"Steroid-Refractory Acute Graft-Versus-Host Disease","Acute Graft-Versus-Host Disease","Graft-Versus-Host Disease","Allogeneic Hematopoietic Stem Cell Transplantation",{"date":398,"type":34},{"date":490,"type":34},"2025-09-01",{"date":492,"type":21},"2027-09",{"name":40,"class":41},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":501,"targetDuration":4,"studyType":22,"phases":503,"briefSummary":505,"conditions":506,"keywords":508,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":514,"leadSponsor":515,"locationsCount":4},"100636563","phase-4-stage-iv-lung-squamous-cell-carcinoma-treated-with-or-without-bronchial-artery-chemoembolization-after-first-line-chemotherapy-and-immunotherapy-100636563","NCT07567313","Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery Chemoembolization After First-line Chemotherapy and Immunotherapy","Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study of Patients With Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery Chemoembolization After First-line Chemotherapy and Immunotherapy","Inclusion Criteria:\n\n1. Squamous cell carcinoma of the lung confirmed by histology or cytology;\n2. According to the TNM staging system of the 9th edition of American Cancer Association, it was assessed as stage IV.\n3. Has received standard first-line chemotherapy immunotherapy for 4\\~6 cycles, and achieved partial remission or disease stability according to the efficacy evaluation of RECIST1.1;\n4. The patient is 18-80 years old;\n5. ECOG PS score is 0-1;\n6. The main organ functions meet the following criteria: (1) Blood routine examination: hemoglobin (HB) ≥ 90g\u002FL; Leukocyte (ANC) ≥ 3.0× 109\u002FL; Neutrophils ≥ 1.5× 109\u002FL; Platelet (PLT) ≥ 75× 109\u002FL; (2) Biochemical examination: albumin (ALB)≥29g\u002FL; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C 2uln; Total bilirubin (TBIL) ≤ 1.5 ULN; Creatinine ≤ 1.5 ULN;\n7. Patients and\u002For their families agree to participate in clinical trials and sign informed consent forms;\n8. No history of other malignant tumors;\n9. No active infection;\n10. Be able to cooperate with research follow-up;\n11. At least one measurable lesion (according to RECIST 1.1);\n12. The expected survival time is more than 3 months.\n\nExclusion Criteria:\n\n1. There is epidermal growth factor receptor (EGFR) sensitive mutation or anaplasticlymphomakinase (ALK) gene translocation;\n2. Have a history of allergy to contrast agents or chemotherapy drugs;\n3. Received other anti-tumor treatments other than standard first-line chemotherapy immunotherapy;\n4. Arrhythmia with myocardial ischemia or myocardial infarction above grade II and poor control (including QTc interval ≥450ms for men and ≥ 470 ms for women);\n5. Coagulation function is seriously abnormal and cannot be corrected;\n6. Hypertension patients still have poor blood pressure control (systolic blood pressure \\> \\>160mmHg, diastolic blood pressure \\> 100 mmhg) after antihypertensive drugs treatment;\n7. Pregnant or lactating female patients;\n8. Have a history of mental illness or psychotropic drug abuse;\n9. Patients with symptomatic brain metastasis;\n10. Patients with autoimmune diseases;",{"count":502,"type":21},166,[504],"PHASE4","This study intends to carry out prospective, randomized controlled clinical trials in many centers across the country to compare the efficacy and safety of immunotherapy after standard first-line chemotherapy or immunotherapy combined with interventional bronchial artery chemoembolization for stage IV lung squamous cell carcinoma.",[507],"Lung Squamous Cell Carcinoma Stage IV",[509,510],"quamous cell carcinoma of the lung","interventional bronchial artery chemoembolization",{"date":512,"type":34},"2026-05-05",{"date":427,"type":21},{"date":293,"type":21},{"name":40,"class":41},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":525,"briefSummary":526,"conditions":527,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":84},"100590657","fmt-for-lung-and-associated-organ-rescue-efficacy-in-mdro-infected-ventilated-patients-100590657","NCT06970262","FMT for Lung and Associated-organ Rescue Efficacy in MDRO-infected Ventilated Patients","FMT for Lung and Associated-organ Rescue Efficacy in Multidrug-resistant Organism (MDRO)-Infected Ventilated Patients: a Single-center, Open-Label, Randomized Controlled Trial","FLARE-MV","Inclusion Criteria:\n\n1. Age 18-70 years, inclusive, irrespective of sex or ethnic background;\n2. Admission to the intensive care unit (ICU) within 24-48 hours;\n3. Anticipated ICU length of stay of ≥7 days, as determined by the attending intensivist prior to enrollment;\n4. Mechanically ventilated patients with MDRO infection;\n5. Provision of written informed consent by the participant or legally authorized representative.\n\nExclusion Criteria:\n\n1. Severe systemic infection during early resuscitation, accompanied by hemodynamic instability, profound tissue hypoperfusion, or life-threatening electrolyte and acid-base disturbances;\n2. Clinician-assessed high risk of mortality within 5 days, or presence of formal treatment-limiting directives (e.g., do-not-intubate or do-not-resuscitate orders);\n3. Active gastrointestinal bleeding or perforation consistent with severe intestinal barrier dysfunction;\n4. Inability to tolerate enteral nutrition providing ≥50% of estimated caloric requirements due to structural intestinal pathology-including fibrotic bowel stenosis or high-output enterocutaneous fistula;\n5. Planned abdominal surgery or history of abdominal surgery within 14 days prior to enrollment;\n6. Confirmed diagnosis of fulminant colitis or toxic megacolon;\n7. Neutropenia defined as absolute neutrophil count \\\u003C 1.5 × 10⁹\u002FL;\n8. Recent exposure to high-risk immunosuppressive or cytotoxic agents within the preceding 3 months, including but not limited to: rituximab (within 6 months), anthracyclines (e.g., doxorubicin), or systemic corticosteroids at ≥20 mg\u002Fday prednisone-equivalent dose for ≥4 consecutive weeks;\n9. Pregnancy or lactation;\n10. Participation in another interventional clinical trial within 3 months prior to enrollment or ongoing at the time of study entry.",{"count":147,"type":21},[24],"Multidrug-resistant organism (MDRO)-infection represents a substantial global health burden. In the intensive care unit (ICU), the concurrent administration of antibiotics, opioids, proton pump inhibitors (PPIs), vasoconstrictors, and parenteral nutrition-compounded by the intrinsic severity of critical illness-induces profound gut microbiota dysbiosis. Accumulating preclinical and clinical evidence indicates that such intestinal dysregulation may trigger distal immunomodulatory and microbial shifts in the lung via the gut-lung axis, thereby contributing to pulmonary microecological imbalance and impairing recovery trajectories. Although pulmonary microecology has garnered increasing scientific attention, the causal and temporal relationship between gut dysbiosis and the establishment or exacerbation of pulmonary microbial dysbiosis in MDRO-infecction remains inadequately characterized. As a result, it is currently unclear whether gut dysbiosis serves as a primary pathogenic driver, a disease-amplifying factor, or a secondary epiphenomenon in the context of MDRO-infecction-associated lung injury.\n\nFecal microbiota transplantation (FMT) is a targeted microbiome-modulating intervention that involves the transfer of functionally diverse, minimally processed microbial communities from comprehensively screened healthy donors to restore ecological stability and functional redundancy in the recipient gut. Robust clinical data demonstrate that FMT effectively decolonizes the gastrointestinal tract of MDROs and reduces the incidence of secondary infections in immunocompetent, non-critically ill populations. Over the past decade, FMT has demonstrated reproducible efficacy in recurrent Clostridioides difficile infection and emerging promise in select extra-intestinal inflammatory conditions-highlighting its capacity as a mechanism-informed strategy for systemic host-microbe recalibration. Given the established role of the gut as a reservoir for enteric pathogens implicated in sepsis, hospital-acquired bloodstream infections, and ventilator-associated pneumonia (VAP), we propose a prospective, single-center, open-Label, randomized controlled trial (RCT) enrolling mechanically ventilated adults with MDRO-infeccted ventilated patients. The primary objective is to evaluate whether adjunctive FMT-delivered via nasojejunal tube-decrease 28-day mortality.",[528,529,530],"Lung Infection","Microbial Colonization","Food Intolerance Syndromes","2026-04-28",{"date":512,"type":34},{"date":534,"type":21},"2026-05-30",{"date":536,"type":21},"2027-12-31",{"name":40,"class":41},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":92,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":84},"100635421","sub-topic-four-clinical-translation-of-original-radioactive-drugs-for-precision-diagnosis-and-treatment-of-gastrointestinal-tumors--clinical-application-value-of-pet-imaging-targeting-lrrc15-in-malignant-tumors-100635421","NCT07552467","Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors","Inclusion Criteria:\n\nEach subject must meet all of the following inclusion criteria to be eligible for study enrollment:\n\n1. The subject or their legally authorized representative (LAR) is capable of providing a signed and dated informed consent form (ICF);\n2. Willing and able to comply with all study procedures and cooperate throughout the entire duration of the study;\n3. Adult patients or healthy volunteers, aged 18 years or older, male or female;\n4. Patients with clinically suspected or confirmed malignancies (supported by evidence such as relevant serum tumor markers, imaging modalities including ultrasound, CT, and MRI, or histopathological examinations) who are in good general condition;\n5. Women of childbearing potential (WOCBP) must have used effective contraception for at least one month prior to screening and agree to continue contraceptive use throughout the study period and for a specified duration following study completion;\n6. Must meet any other protocol-specified inclusion criteria.\n\nExclusion Criteria:\n\nAny subject meeting any of the following baseline criteria will be excluded from the study:\n\n1. Inability to tolerate or complete PET\u002FMR or PET\u002FCT examinations (including, but not limited to, the inability to lie supine, claustrophobia, radiophobia, etc.);\n2. Presence of other comorbidities, such as acute systemic illnesses and electrolyte imbalances;\n3. Known allergy or hypersensitivity to the LRRC15 radiotracer or its synthetic excipients; fasting blood glucose level exceeding 11.0 mmol\u002FL prior to \\[¹⁸F\\]FDG injection;\n4. Patients deemed by the investigator to have poor expected compliance;\n5. Pregnant or lactating (nursing) women;\n6. Presence of any other conditions or factors that, in the opinion of the investigator, would make the subject unsuitable for participation in this trial.",{"count":545,"type":21},26,"This project utilizes LRRC15-specific targeted PET radiotracers to perform PET\u002FMR or PET\u002FCT imaging on healthy volunteers and patients with clinically suspected or confirmed malignancies characterized by high LRRC15 expression-including pancreatic cancer, breast cancer, lung cancer, sarcoma, head and neck tumors, glioblastoma, colorectal cancer, and melanoma. The study aims to achieve the following objectives:\n\nFor patients with malignant tumors: To diagnose and stage the disease. By comparing the imaging results against the gold standard of histopathological diagnosis, the study aims to evaluate diagnostic efficacy, ascertain the presence or absence of lesions, and characterize their anatomical location and nature. Furthermore, through comparison with \\[¹⁸F\\]FDG PET or \\[⁶⁸Ga\\]Ga-FAPI PET, the study seeks to achieve accurate disease staging, assess tumor burden, and facilitate therapeutic decision-making.\n\nFor healthy volunteers: To conduct pharmacokinetic analyses to determine the in vivo biodistribution and metabolic patterns of the radiotracer, as well as to evaluate its safety profile.",[287,548,549,550,551,552,553,554],"Breast Cancer","Lung Cancer","Sarcoma","Head and Neck Tumors","Glioblastoma","Colorectal Cancer","Melanoma",{"date":556,"type":34},"2026-04-27",{"date":558,"type":34},"2026-04-01",{"date":560,"type":21},"2027-03-31",{"name":40,"class":41},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":190,"minAge":260,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":22,"phases":571,"briefSummary":572,"conditions":573,"keywords":577,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":581,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":431},"100635424","clinical-study-on-the-preservation-of-ovarian-function-in-patients-with-aplastic-anemia-following-allogeneic-hematopoietic-stem-cell-transplantation-using-goserelin-100635424","NCT07552506","Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin","Inclusion Criteria:\n\n(1) Patients clinically diagnosed with SAA and scheduled for allogeneic haematopoietic stem cell transplantation (allo-HSCT); (2) Female patients aged 14 to 50 years, within reproductive age, with regular menstrual cycles prior to transplantation; (3) Patients or their legal representatives voluntarily participate and sign informed consent forms, demonstrating comprehension and willingness to comply with all study procedures and requirements; (4) Patients with an estimated survival period exceeding one year to ensure sufficient time for monitoring menstrual recovery.\n\nExclusion Criteria:\n\n(1) Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may compromise study outcomes or increase patient risk; (2) Patients with a history of allergy to goserelin or related medications; (3) Patients who have previously undergone menopause due to physiological or pathological factors; (4) Patients with a history of gynaecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; (5) Patients currently participating in other clinical studies that may influence menstrual recovery; (6) Patients who refuse to participate in this clinical study.","50 Years",{"count":570,"type":21},132,[24],"This study is a prospective, randomized, controlled, multicenter clinical trial. It plans to enroll 132 female SAA patients aged 14-50 years from multiple medical centers nationwide who are scheduled to undergo allo-HSCT. Patients will be divided into two groups based on whether they receive busulfan conditioning: the busulfan-conditioned group (Bu group) and the non-busulfan-conditioned group (non-Bu group). Within each group, patients will be randomly assigned 1:1 to either the experimental group (Goserelin prophylaxis group) or the control group using a random number table. The experimental group will receive a single 3.6 mg subcutaneous injection of Goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group will not receive Goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplant (defined as ≥3 naturally occurring menstrual cycles without intervention by menstrual-regulating drugs). Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; Additional reproductive parameters: ovarian and uterine volume, endometrial thickness; time to neutrophil\u002Fplatelet engraftment; incidence of acute\u002Fchronic graft-versus-host disease (aGVHD\u002FcGVHD), EBV\u002FCMV infection rates; transplant-related mortality; and adverse event (AE) occurrence. This study aims to evaluate the efficacy and safety of goserelin in preserving ovarian function following allo-HSCT.",[574,575,576],"Aplastic Anaemia (AA)","Allogeneic Haematopoietic Stem Cell Transplantation","Ovarian Insufficiency",[578,579,580],"Aplastic anaemia","Allogeneic haematopoietic stem cell transplantation","Ovarian insufficiency",{"date":556,"type":34},{"date":583,"type":21},"2026-05-01",{"date":585,"type":21},"2027-10-01",{"name":40,"class":41},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":190,"minAge":260,"maxAge":568,"enrollmentInfo":593,"targetDuration":4,"studyType":22,"phases":595,"briefSummary":596,"conditions":597,"keywords":599,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":601,"startDateStruct":602,"completionDateStruct":603,"leadSponsor":604,"locationsCount":431},"100635422","clinical-study-on-the-preservation-of-ovarian-function-following-hematopoietic-stem-cell-transplantation-in-patients-with-malignant-hematologic-diseases-using-goserelin-100635422","NCT07552480","Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using Goserelin","Inclusion Criteria:\n\n1\\. Patients with malignant hematologic disorders scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT); 2. Female patients aged 14 to 50 years, within reproductive age, with regular menstrual cycles prior to transplantation; 3. Patients or their legal representatives voluntarily participate and sign informed consent forms, demonstrating ability to understand and comply with all study procedures and requirements; 4. Expected survival exceeding 1 year to ensure sufficient time for monitoring menstrual recovery.\n\nExclusion Criteria:\n\n1\\. Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may affect study outcomes or increase patient risk; 2. Patients with a history of allergy to goserelin or other related medications; 3. Patients who have already undergone menopause due to physiological or pathological factors; 4. Patients with a history of gynecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; 5. Patients currently participating in other clinical studies that may affect menstrual recovery; 6. Patients who refuse to participate in this clinical study.",{"count":594,"type":21},64,[24],"This study is a prospective, multicenter, randomized controlled clinical trial planned to enroll 64 female patients with malignant hematologic diseases aged 14-50 years who are scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients will be divided into two groups based on the use of myeloablative conditioning: the myeloablative conditioning (MAC) group and the non-MAC conditioning group. The non-MAC group refers to a primary conditioning regimen where the main conditioning agents-busulfan (Bu) ≤ 6.4 mg\u002Fkg, melphalan (Mel) ≤ 140 mg\u002Fm², and thiotepa ≤ 10 mg\u002Fkg-are combined. Patients receiving this primary chemotherapy regimen will be assigned to the MAC group. Within each group (MAC or non-MAC), patients were randomly assigned 1:1 to either the experimental group (goserelin prophylaxis) or the control group using a random number table. The experimental group received a single 3.6 mg subcutaneous injection of goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group did not receive goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplantation. Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; other reproductive indicators: ovarian volume, endometrial thickness; Neutrophil\u002Fplatelet engraftment time; Complications: incidence of acute\u002Fchronic graft-versus-host disease (aGVHD\u002FcGVHD), EBV\u002FCMV infection rates; Disease recurrence rate; Transplant-related mortality; Adverse event (AE) occurrence. This study aims to evaluate the efficacy and safety of goserelin in improving ovarian function following hematopoietic stem cell transplantation in patients with malignant hematologic diseases.",[575,598,576],"Malignant Hematologic Disease",[600,579,580],"Malignant Hematologic Diseases",{"date":556,"type":34},{"date":583,"type":21},{"date":585,"type":21},{"name":40,"class":41},""]